The study evaluated 131 patients with chronic post-transfusion hepatitis C who were referred to a tertiary care center between 1980 and 1994. The patients had a mean age of 57 years at initial evaluation, with a mean age at blood transfusion of 35 years. Most patients had cirrhosis (51.1%) or chronic active hepatitis (22.9%), while 7% had hepatocellular carcinoma. The mean follow-up period was 3.9 years, during which 20 patients died, mostly from complications of cirrhosis or hepatocellular carcinoma. The study found that chronic post-transfusion hepatitis C is a progressive disease that can lead to liver failure or hepatocellular carcinoma in some patients. The natural history of HCV infection acquired through blood transfusion remains unclear, but the study suggests a slow progression from acute infection to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The study also found that HCV is the principal cause of chronic hepatitis in post-transfusion non-A, non-B hepatitis. The results indicate that screening blood products for HCV before transfusion can reduce the incidence of post-transfusion HCV infection. For those already infected, antiviral therapy may help eradicate the virus and halt the progression of chronic liver disease. The study highlights the importance of early detection and treatment of HCV infection to prevent serious complications.The study evaluated 131 patients with chronic post-transfusion hepatitis C who were referred to a tertiary care center between 1980 and 1994. The patients had a mean age of 57 years at initial evaluation, with a mean age at blood transfusion of 35 years. Most patients had cirrhosis (51.1%) or chronic active hepatitis (22.9%), while 7% had hepatocellular carcinoma. The mean follow-up period was 3.9 years, during which 20 patients died, mostly from complications of cirrhosis or hepatocellular carcinoma. The study found that chronic post-transfusion hepatitis C is a progressive disease that can lead to liver failure or hepatocellular carcinoma in some patients. The natural history of HCV infection acquired through blood transfusion remains unclear, but the study suggests a slow progression from acute infection to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The study also found that HCV is the principal cause of chronic hepatitis in post-transfusion non-A, non-B hepatitis. The results indicate that screening blood products for HCV before transfusion can reduce the incidence of post-transfusion HCV infection. For those already infected, antiviral therapy may help eradicate the virus and halt the progression of chronic liver disease. The study highlights the importance of early detection and treatment of HCV infection to prevent serious complications.